Free Trial
NASDAQ:HURA

TuHURA Biosciences (HURA) Stock Price, News & Analysis

TuHURA Biosciences logo
$2.83 -0.18 (-5.98%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.88 +0.05 (+1.77%)
As of 05/23/2025 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About TuHURA Biosciences Stock (NASDAQ:HURA)

Key Stats

Today's Range
$2.82
$3.28
50-Day Range
$2.83
$4.23
52-Week Range
$1.80
$7.93
Volume
110,925 shs
Average Volume
243,796 shs
Market Capitalization
$123.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67
Consensus Rating
Buy

Company Overview

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Receive HURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TuHURA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HURA Stock News Headlines

Zacks Small Cap Issues Pessimistic Outlook for HURA Earnings
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
Research Analysts Offer Predictions for HURA FY2027 Earnings
What is HC Wainwright's Forecast for HURA FY2025 Earnings?
HURA: First Quarter 2025 Results
See More Headlines

HURA Stock Analysis - Frequently Asked Questions

TuHURA Biosciences' stock was trading at $4.09 at the start of the year. Since then, HURA stock has decreased by 30.8% and is now trading at $2.83.
View the best growth stocks for 2025 here
.

TuHURA Biosciences (NASDAQ:HURA) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.02.

TuHURA Biosciences' top institutional investors include Apollon Wealth Management LLC (0.26%), Suncoast Equity Management (0.23%), Sabal Trust CO (0.09%) and Hurlow Wealth Management Group Inc. (0.07%).

Shares of HURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/15/2025
Today
5/23/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HURA
Previous Symbol
NASDAQ:HURA
Web
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.67
High Stock Price Target
$15.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+347.6%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($4.11) per share
Price / Book
-0.69

Miscellaneous

Free Float
42,200,000
Market Cap
$123.61 million
Optionable
N/A
Beta
0.53
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:HURA) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners